Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dexa-BEAM)

Annals of Oncology

Volumn 9, Issue 3, 1998, Pages 289-295

  Josting, A ^a   Katay I ^a   Rueffer, U ^a   Winter, S ^a   Tesch, H ^a   Engert, A ^a   Diehl, V ^a   Wickramanayake, P D ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

ABMT; Dexa BEAM regimen; High dose chemotherapy; Hodgkin's disease; PBSCT

Indexed keywords

CARMUSTINE; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; MELPHALAN;

ADULT; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG MEGADOSE; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HODGKIN DISEASE; HUMAN; MALE; NEUTROPENIA; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 0031967030     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008283909959     Document Type: Article

References (35)

1. Longo DL, Duffey PL, Young RC et al. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: The low probability of cure. J Clin Oncol 1992; 10: 210-6.
2. Cannellos GP. Is there an effective salvage therapy for advanced Hodgkin's disease? Ann Oncol 1991; 2 (Suppl 1): 1-7.
3. Cannellos GP. The second chance for advanced Hodgkin's disease. J Clin Oncol 1992; 10: 175-6.
4. Buzaid AC, Lippman SC, Miller TP. Salvage therapy of advanced Hodgkin's disease: Critical appraisal of curative potential. Am J Med 1987; 83: 523-32.
5. Biermann PJ, Vose JM, Armitage JO. Autologous transplantation for Hodgkin's disease: Coming of Age? Blood 1994; 5 (1): 1161-4.
6. Vose JM, Phillips GL, Armitage JO. Autologous bone marrow transplantation for Hodgkin's disease. In Armitage JO, Antman KH (eds): High-Dose Cancer Therapy. Pharmacology, Hematopoietins, Stem Cells. Baltimore, MD: Williams & Wilkins 1992; 651-66.
7. Reece DE, Barnett MJ, Connors JM et al. Intensive chemotherapy with cyclophosphamide. carmustine and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol 1992; 9 (10): 1871-9.
8. Biermann PJ, Bagin RG, Jagannath S et al. High-dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: Long term follow-up in 128 patients. Ann Oncol 1993;4:767-73.
9. Reece DE, Connors JM, Spinelli JJ et al. Intensive therapy with cyclophosphamide, carmustine, etoposide +/- cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy. Blood 1994; 83 (5): 1193-9.
10. Jones RJ, Piantadosi S, Mann RB et al. High-dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol 1990; 8: 527-32.
11. Armitage JO, Biermann PJ, Vose JM et al. Autologous bone marrow transplantation for patients with relapsed Hodgkin's disease. Am J Med 1991; 91: 605-610.
12. Gianni AM, Siena S, Bregni M et al. Prolonged disease-free survival after high-dose sequential chemo-radiotherapy and haematopoietic autologous transplantation in poor prognosis Hodgkin's disease. Ann Oncol 1991; 2: 645-61.
13. Chopra R, McMillan AK, Linch DC et al. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients. Bood 1993; 5 (1): 1137-40.
14. Crump M, Smith AM, Brandwein J et al. High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: Importance of disease status at transplant. J Clin Oncol 1993; 11 (4): 704-711.
15. Rappoport AP, Rowe JM, Kouides PA et al. One hundred autotransplants for relapsed or refractory Hodgkin's disease and lymphoma: Value of pretransplant disease status for predicting outcome. J Clin Oncol 1993; 11 (12): 2351-61.
16. Yahalom J, Gulati SC, Toia M et al. Accelerated hyperfractionated total-lymphoid irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for refractory and relapsing patients with Hodgkin's disease. J Clin Oncol 1993; 11: 2351-70.
17. Gribben JG, Linch DC, Singer CRJ, McMillan AK. Successful treatment of refractory Hodgkin's disease by high-dose combination chemotherapy and autologous bone marrow transplantation. Blood 1989; 73 (1): 340-4.
18. Jagannath S, Dicke KA, Armitage JO, Cabanillas FF. High-dose cyclophosphamide, carmustine and etoposide and autologous bone marrow transplantation for relapsed Hodgkin's disease. Ann Intern Med 1986; 104: 163-6.
19. Phillips GL, Wolff SN, Herzig RH et al. Treatment of progressive Hodgkin's disease with intensive chemoradiotherapy and autologous bone marrow transplantation. Blood 1989; 73 (3): 2086-92.
20. Carella AM, Congiu AM, Gaozza E et al. High-dose chemotherapy with autologous bone marrow transplantation in 50 advanced resistant Hodgkin's disease patients: An Italian study group report. J Clin Oncol 1988; 6: 1411-5.
21. Thomas ED, Storb R. Technique for human marrow grafting. Blood 1970; 36: 507-11.
22. Kessinger A, Biermann PJ, Vose JM, Armitage JO. High-dose cyclophosphamide, carmustine and etoposide followed by autologous peripheral stem cell transplantation for patients with relapsed Hodgkin's disease. Blood 1991; 11 (1): 2322-5.
23. Nademanee A, O'Donnell MR. Snyder DS et al. High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow transplantation and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease: Results in 85 patients with analysis of prognostic factors. Blood 1995; 85 (5): 1381-90.
24. Broun ER, Tricot G, Akard L. Treatment of refractory lymphoma with high-dose cytarabine, cyclophosphamide and either TBI or VP-16 followed by autologous bone marrow transplantation. BMT 1990; 5: 431-44.
25. Lohri A, Barnett M, Fairey RN et al. Outcome of treatment of first relapse of Hodgkin's disease after primary chemotherapy: Identification of risk factors from the British Columbia Experience 1970 to 1988. Blood 1991; 10 (15): 2292-8.
26. Pfreundschuh MG, Schoppe WD, Fuchs R et al. Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine, procarbacine, and prednisone (COPP) and doxorubicine, bleomycin, vinblastine, and darcarbazine (ABVD): A multi-center trial of the German Hodgkin's study group. Cancer Treat Rep 1987; 71: 1203-8.
27. Hagemeister FB, Tannir N, McLaughlin P et al. MIME chemotherapy (methyl-GAG. ifosphamide, methotrexate, etoposide) as treatment for recurrent Hodgkin's disease. J Clin Oncol 1987; 5: 556-61.
28. Cervantes F, Reverter JC, Montserrat E, Rozman C. Treatment of advanced resistant Hodgkin's disease with lomustine, etoposide and prednimustine. Cancer Treat Rep 1989; 70: 665.
29. Linch DC, Winfield D, Goldstone AH et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNL1 randomized trial. Lancet 1993; 341: 1051-54.
30. Ahmed T, Ciavarella D, Feldman E et al. High-dose potentially myeloablative chemotherapy and autologous bone marrow transplantation for patients with advanced Hodgkin's disease. Leukemia 1989; 3: 19-22.
31. Hurd DD, Haake RJ, Lasky LC. Treatment of refractory and relapsed Hodgkin's disease: Intensive chemotherapy and autologous bone marrow or peripheral blood stem cell support. Med Pediatr Oncol 1990; 18: 447-53.
32. Jagannath S, Armitage JO, Dicke KA et al. Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol 1989; 7 (2): 179-185.
33. Skipper HE. Stepwise progress in the treatment of disseminated cancers. Cancer 1983; 51: 1773-6.
34. Bender JG, Unverzagt KL, Walker DE. Identification and comparison of CD34 positive cells and their subpopulations from normal peripheral blood and bone marrow using flow cytometry. Blood 1991; 77: 2591-5.
35. Leary AG, Ogawa M, Strauss LC. Single cell origin of multilineage colonies in culture. J Cin Invest 1984; 84: 2193-6.